Showing results (21-30 of 359) with videos related to
Sort By:
Pageof 36
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2013
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumoursStefano Severi, Oriana Nanni, Lisa Bodei, et al.Neuroendocrinology|February 9, 2013
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumorsMaddalena Sansovini, Stefano Severi, Alice Ambrosetti, et al.Cancer Biotherapy & Radiopharmaceuticals|May 5, 2009
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistributionDemetrio Aricò, Chiara Maria Grana, Anna Vanazzi, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 17, 2010
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumorsValentina Ambrosini, Davide Campana, Lisa Bodei, et al.Cancer Biotherapy & Radiopharmaceuticals|July 10, 2014
Planning combined treatments of external beam radiation therapy and molecular radiotherapyMarta Cremonesi, Mahila Ferrari, Francesca Botta, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 4, 2013
Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical studyFrancesca Botta, Marta Cremonesi, Mahila E Ferrari, et al.Cancer Biotherapy & Radiopharmaceuticals|December 23, 2009
Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOCMaribel L Sierra, Alberto Agazzi, Lisa Bodei, et al.European Journal of Nuclear Medicine and Molecular Imaging|July 12, 2008
Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatmentMarta Cremonesi, Mahila Ferrari, Mirco Bartolomei, et al.Nuclear Medicine and Biology|February 4, 2010
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin)Stefano Papi, Luigi Martano, Lucia Garaboldi, et al.Neuro-Oncology|October 1, 2024
Do we need dosimetry for the optimization of theranostics in CNS tumors?Francesco Cicone, Silvano Gnesin, Giulia Santo, et al.Pageof 36